Syncom Formulations (India) Limited (NSE:SYNCOMF)
16.14
-0.18 (-1.10%)
May 2, 2025, 3:29 PM IST
NSE:SYNCOMF Revenue
Syncom Formulations (India) had revenue of 1.28B INR in the quarter ending December 31, 2024, with 95.78% growth. This brings the company's revenue in the last twelve months to 3.91B, up 56.41% year-over-year. In the fiscal year ending March 31, 2024, Syncom Formulations (India) had annual revenue of 2.63B with 17.45% growth.
Revenue (ttm)
3.91B
Revenue Growth
+56.41%
P/S Ratio
3.90
Revenue / Employee
3.91M
Employees
998
Market Cap
15.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
Mar 31, 2021 | 2.45B | 392.94M | 19.12% |
Mar 31, 2020 | 2.06B | 187.39M | 10.03% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |